Aradigm Reports Successful ORBIT-1 Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin - Drugs.com MedNews
Links shared publicly online about this topic.
- 215total visits
Aradigm Reports Successful ORBIT-1 Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin - Drugs.com MedNews
Both ARD-3100 Doses Met Primary Endpoint 2 mL Dose Found Equipotent to 3 mL Dose, with Excellent Safety and Tolerability Jun 16, 2011 - Aradigm Corporation (OTC
View full resource at drugs.com
Tags: Bronchiectasis, Drug, Antibiotic, Cipro, Ciprobay, Safety
Most Recently Shared on June 16, 2011 at 1:08 pm By:
Aradigm Reports Successful ORBIT-1 Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin: Both ARD-310... http://bit.ly/mBxNZC #drug
Aradigm Reports Successful ORBIT-1 Bronchiectasis Study With Inhaled Liposomal Ciprofloxacin
medicalnewstoday.com — “Aradigm Corporation (OTCBB:ARDM) (the Company) today announced positive top line data from its recently concluded Phase 2b study (Once-Daily Respiratory Bronchiectasis Inhalation Treatment - ORB” View full resource at medicalnewstoday.com
Most Recently Shared on June 17, 2011 at 4:05 pm By:
MNT Cystic Fibrosis Health News
Aradigm Reports Successful ORBIT-1 Bronchiectasis Study With Inhaled Liposomal Ciprofloxacin http://mnt.to/3Xmt #cysticfibrosis
Advertisement
